A Goal Date for the Possible FDA Approval of Xgeva® (Denosumab) for men with Advanced Prostate Cancer
Amgen (NASDAQ: AMGN) today published a press release that said the U.S. Food and Drug Administration (FDA) will target an action date of April 26, 2012 for the supplemental Biologics License Application (sBLA) (approval) to [...]
Genome-wide Association Study Identifies a Genetic Variant Associated with Risk for More Aggressive Prostate Cancer
It is estimated that in the United States 200,000 men will be diagnosed with prostate cancer each year with approximately 20% to 30% having clinically aggressive prostate cancer. When diagnosed the standard is to consider [...]
Identifying A New Pathway Explaining Resistance to Prostate Cancer Treatment
We al are very familiar with the significant problem in the treatment of prostate cancer, even therapies that initially work stop working and our disease continues to progress. The inevitable onset of this resistance to [...]
Decreased Prostate Cancer-Specific Survival of Men with BRCA2 Mutations and for Men from Breast Cancer Families
It is fairly common practice for those diagnosed with breast cancer to have genetic testing. Genetic testing is almost unheard of when men are diagnosed with prostate cancer. Current research shows that genetic testing for [...]
A Provenge Like Treatment Demonstrates Extraordinary Results Treating Leukemia – A Phase I Trial Using the Technique In Post Chemo Prostate Cancer Treatment
The most exciting news today is about some research performed at the University of Pennsylvania where researchers took blood from the three leukemia patients and isolated the T cells, a type of immune cell in [...]
Towards An Understanding of the Role of Genetics in Determining Future Treatment Options in Advanced Prostate Cancer – SLCO2B1 and SLCO1B3
We have heard for a period of time that the future of cancer treatment is in genetics. Despite the hubbub, we see very little hard evidence of this in today’s current treatment decisions. Treatment still [...]